Terminology Service < Semantic Lookup Platform

All terms in NCIT

Label	Id	Description
Stage 0 Vaginal Cancer AJCC v6	NCIT_C7855	[Stage 0 includes: (Tis, N0, M0). Tis: Carcinoma in situ. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th ed.)]
Vaginal Cancer by AJCC v6 Stage	NCIT_C90347	[A term that refers to the staging of vaginal cancer according to the American Joint Committee on Cancer, 6th edition.]
High Grade Vaginal Intraepithelial Neoplasia	NCIT_C7663	[Vaginal intraepithelial neoplasia characterized by the presence of moderate or severe dysplastic changes.]
Stage I Vaginal Cancer AJCC v6 and v7	NCIT_C7856	[Stage I includes: (T1, N0, M0). T1: Tumor confined to vagina. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)]
Vaginal Cancer by AJCC v7 Stage	NCIT_C91204	[A term that refers to the staging of vaginal cancer according to the American Joint Committee on Cancer, 7th edition.]
Stage II Vaginal Cancer AJCC v6 and v7	NCIT_C7857	[Stage II includes: T2, N0, M0. T2: Tumor invades paravaginal tissues but not to pelvic wall. N0: No regional lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)]
DS Stage I Plasma Cell Myeloma	NCIT_C7850	[Plasma cell myeloma with all of the following: 1. Hemoglobin greater than 10 g/Dl, 2. Normal serum calcium, 3. Normal bone structure, 4. Low monoclonal (or myeloma) protein (M protein) production as shown by: a. IgG less than 5.0 g/dL, b. IgA less than 3.0 g/dL, c. Urinary kappa or lamda less than 4 g/24 hours. Estimated myeloma cell mass: less than 0.6 trillion (1012)/m2 (low burden). The following subclassification of stages is used: a. Creatinine less than 2.0 mg/dL, b. Creatinine greater than or equal to 2.0 mg/dL. Impaired renal function worsens prognosis regardless of stage. Note that the newer International Staging System defines stage I quite differently: Beta-2-microglobulin less than 3.5 and albumin greater than or equal to 3.5 (median survival of 62 months). (PDQ)]
Plasma Cell Myeloma by DS Stage	NCIT_C139008	[A header term that refers to the staging of plasma cell myeloma according to the Durie/Salmon staging system.]
DS Stage II Plasma Cell Myeloma	NCIT_C7851	[Plasma cell myeloma that fits in neither stage I nor stage III. Estimated myeloma cell mass: 0.6 to 1.2 trillion (1012)/m2 (intermediate burden). The following subclassification of stages is used: a. Creatinine less than 2.0 mg/dL, b. Creatinine greater than or equal to 2.0 mg/dL. Impaired renal function worsens prognosis regardless of stage. Note that the newer International Staging System defines stage II quite differently: Beta-2-microglobulin less than 3.5 and albumin less than 3.5 or beta-2-microglobulin 3.5 to less than 5.5 (median survival of 44 months). (PDQ)]
DS Stage III Plasma Cell Myeloma	NCIT_C7852	[Plasma cell myeloma with one or more of the following: 1. Hemoglobin less than 8.5 g/dL. 2. Serum calcium greater than 12.0 mg/dL. 3. More than three lytic bone lesions. 4. High M protein production as shown by: a. IgG greater than 7.0 g/dL. b. IgA greater than 5.0 g/dL. c. Urinary kappa or lamda greater than 12.0 g/24 hours. Estimated myeloma cell mass: greater than 1.2 trillion (1012)/m2 (high burden). The following subclassification of stages is used: a. Creatinine less than 2.0 mg/dL. b. Creatinine greater than or equal to 2.0 mg/dL. Serum beta-2-microglobulin has been shown to be a reliable marker for prognosis. Since the great majority of symptomatic myeloma patients are classified as stage III by the Durie/Salmon criteria, this staging system has not proven to be very useful for identifying the patients with intermediate and poor prognosis. Note that the newer International Staging System defines stage III quite differently: Beta-2-microglobulin greater than or equal to 5.5 (median survival of 29 months). (PDQ)]
Lung Small Cell Carcinoma	NCIT_C4917	[A highly aggressive subtype of lung carcinoma characterized by the presence of malignant small cells and necrosis. Metastatic disease is usually present at the time of diagnosis.]
Stage III Vaginal Cancer AJCC v6 and v7	NCIT_C7858	[Stage III includes: (T1-3, N1, M0) and (T3, N0, M0). T1: Tumor confined to vagina. T2: Tumor invades paravaginal tissues but not to pelvic wall. T3: Tumor extends to pelvic wall. N0: No regional lymph node metastasis. N1: Pelvic or inguinal lymph node metastasis. M0: No distant metastasis. (AJCC 6th and 7th eds.)]
Stage IVA Vaginal Cancer AJCC v6 and v7	NCIT_C7859	[Stage IVA includes: T4, Any N, M0. T4: Tumor invades mucosa of the bladder or rectum and/or extends beyond the true pelvis (bullous edema is not sufficient evidence to classify a tumor as T4). M0: No distant metastasis. (AJCC 6th and 7th eds.)]
Stage IV Vaginal Cancer AJCC v6 and v7	NCIT_C7597	[Stage IV includes: IVA: (T4, Any N, M0) and IVB: (Any T, Any N, M1). T4: Tumor invades mucosa of the bladder or rectum and/or extends beyond the true pelvis (bullous edema is not sufficient evidence to classify tumor as T4). M0: No distant metastasis. M1: Distant metastasis. (AJCC 6th and 7th eds.)]
PHLDA2 wt Allele	NCIT_C54399	[Human PHLDA2 wild-type allele is located in the vicinity of 11p15.5 and is approximately 1 kb in length. This allele, which encodes pleckstrin homology-like domain family A member 2 protein, is involved in tumor suppression. Aberrant alterations in this region generate variant alleles that are associated with Beckwith-Wiedemann syndrome, Wilms tumor, rhabdomyosarcoma, adrenocortical carcinoma, and lung, ovarian, and breast cancer.]
TUSC2 wt Allele	NCIT_C54391	[Human TUSC2 wild-type allele is located in the vicinity of 3p21.3 and is approximately 3 kb in length. This allele, which encodes tumor suppressor candidate 2 protein, plays a putative role in cell cycle arrest and the induction of apoptosis. Loss of TUSC2 gene function is associated with several types of lung cancer.]
TUSC2 Gene	NCIT_C24409	[This gene plays a putative role in apoptosis and the negative regulation of cell growth.]
Advanced Malignant Mesothelioma	NCIT_C7865	[A malignant mesothelioma that has spread beyond its original site of growth.]
Advanced Malignant Neoplasm	NCIT_C9270	[A malignant neoplasm that has spread extensively to other anatomic sites or is no longer responding to treatment.]
Cellular Stratification	NCIT_C54392